Generation and ex vivo expansion of HTLV-1 specific CD8+ cytotoxic T-lymphocytes for adoptive immunotherapy

Biotechnology and Bioengineering

Volumn 50, Issue 5, 1996, Pages 529-540

  Peshwa, Madhusudan V ^a   Page, Laura A ^a   Qian, Lichuan ^a   Yang, Demao ^a   Van Schooten, Wim C A ^a  

^a Activated Cell Therapy   (United States)

Author keywords

CTL; Dendritic cell; HTLV 1; Immunotherapy; T lymphocytes

Indexed keywords

AMINO ACIDS; ANIMAL CELL CULTURE; ANTIGEN-ANTIBODY REACTIONS; ANTIGENS; BIOASSAY; BLOOD; CYTOLOGY; IMMUNOLOGY; ONCOGENIC VIRUSES; PATIENT TREATMENT; PROTEINS; TOXICITY;

ANTIGEN PRESENTING CELLS; CYTOTOXIC T LYMPHOCYTES; CYTOTOXICITY ASSAY; DENDRITIC CELLS; HUMAN LEUCOCYTE ANTIGEN; HUMAN TROPHIC LEUKEMIA VIRUS; IMMUNOTHERAPY; INTERLEUKIN;

CELLS;

CD8 ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ANTIBODY RESPONSE; ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; ARTICLE; CELL KILLING; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HUMAN; HUMAN CELL; HUMAN T CELL LEUKEMIA VIRUS 1; IMMUNE RESPONSE; TARGET CELL; TUMOR ASSOCIATED LEUKOCYTE;

EID: 0030570261     PISSN: 00063592     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0290(19960605)50:5<529::aid-bit7>3.0.co;2-h     Document Type: Article

References (46)

1. - tumor-infiltrating lymphocytes. J. Exp. Med. 173: 647-658.
2. Coulie, P. G., Somville, M., Lehmann, F., Hainaut, P., Brasseur, F., Devos, R., Boon, T. 1992. Precursor frequency analysis of human cytolytic lymphocytes directed against autologous melanoma cells. Int. J. Cancer 50: 289-297.
3. de The, G., Bomford, R. 1993. An HTLV-1 vaccine: Why, how, for whom? AIDS Res. Hum. Retrovir. 9: 381-386.
4. Disis, M. L., Smith, J. W., Murphy, A. E., Chen, W., Cheever, M. A. 1994. In vitro generation of human cytolytic T-cells specific for peptides derived from the HER-2/neu protooncogene protein. Cancer Res. 54: 1071-1076.
5. Elovaara, I., Koenig, S., Brewah, A. Y., Woods, R. M., Lehky, T., Jacobson, S. 1993. High human T cell lymphotropic virus type 1 (HTLV-1)-specific precursor cytotoxic T lymphocyte frequencies in patients with HTLV-1 associated neurological disease. J. Exp. Med. 177: 1567-1573.
6. Freedman, R. S., Edwards, C. L., Kaavanagh, J. J., Kudelka, A. P., Katz, R. L., Carrasco, C. H., Atkinson, E. N., Scott, W., Tomasovic, B., Templin, S., Platsoucas, C. D. 1994. Intraperitoneal adoptive immunotherapy of ovarian carcinoma with tumor-infiltrating lymphocytes and low-dose recombinant interleukin-2: A pilot trial. J. Immunother. 16: 198-210.
7. Gallo, R. C. 1995. Human retroviruses in the second decade: A personal perspective. Nature Med. 1: 753-759.
8. Grabbe, S., Beissert, S., Schwarz, T., Granstein, R. D. 1995. Dendritic cells as initiators of tumor immune responses: A possible strategy for tumor immunotherapy. Immunol. Today 16: 117-121.
9. Graham, S., Babayan, R. K., Lamm, D. L., Sawczuk, I., Ross, S. D., Lavin, P. T., Osband, M. E., Krane, R. J 1993. The use of ex vivo-activated memory T cells (autolymphocyte therapy) in the treatment of metastatic renal cell carcinoma: Final results from a randomized, controlled, multisite study. Sem. Urol. 11: 27-34.
10. Greenberg, P. D. 1991. Adoptive T cell therapy of tumors: Mechanisms operative in the recognition and elimination of tumor cells. Adv. Immunol. 49: 281-355.
11. Guery, J-C., Adorini, L. 1995. Dendritic cells are the most efficient in presenting endogenous naturally processed self-epitopes to class II-restricted T cells. J. Immunol. 154: 536-544.
12. + tumor-specific T cell clones derived from human melanoma-infiltrating lymphocytes in response to autologous tumor cells in vitro. Eur. J. Immunol. 24: 1966-1973.
13. - T lymphocytes in patients with acquired immunodeficiency syndrome (AIDS)-related complex or AIDS. Blood 81: 2093-2101.
14. Hosmalin, A., Kumar, S., Barnd, D., Houghten, R., Smith, G. E., Hughes, S. H., Berzofsky, J. A. 1992. Immunization with soluble protein-pulsed spleen cells induces class I-restricted cytotoxic T lymphocytes that recognize immunodominant epitopic peptides from Plasmodium falciparum and HIV-1. J. Immunol. 149: 1311-1318.
15. Johnson, R. P., Hammond, S. A., Trocha, A., Siliciano, R. F., Walker, B. D. 1994. Induction of a major histocompatibility complex class I-restricted cytotoxic T lymphocyte response to a highly conserved region of human immunodeficiency virus type 1 (HIV-1) gp120 in seronegative humans immunized with a candidate HIV-1 vaccine. J. Virol. 68: 3145-3153.
16. Kannagi, M., Shida, H., Igarashi, H., Kuruma, K., Murai, H., Aono, Y., Maruyama, I., Osame, M., Hattori, T., Inoko, H. 1992. Target epitope in the Tax protein of human T-cell leukemia virus type I recognized by class I major histocompatability complexrestricted cytotoxic T cells. J. Virol. 66: 2928-2933.
17. Kos, F. J., Mullbacher, A. 1992. Induction of primary anti-viral cytotoxic T cells by in vitro stimulation with short synthetic peptide and interleukin-7. Eur. J. Immunol. 22: 3183-3185.
18. + cytotoxic T-lymphocytes. AIDS 6: 643-649.
19. Macatonia, S. E., Patterson, S., Knight, S. C. 1991. Primary proliferative and cytotoxic T-cell responses to HIV induced in vitro by human dendritic cells. Immunology 74: 399-406.
20. Marcus, S. G., Perry-Lalley, D., Mule, J. J., Rosenberg, S. A., Yang, J. C. 1994. The use of interleukin-6 to generate tumorinfiltrating lymphocytes with enhanced in vivo antitumor activity. J. Immunother. 15: 105-112.
21. Markowicz, S., Engleman, E. G. 1990. Granulocyte-macrophage colony-stimulating factor promotes differentiation and survival of human peripheral blood dendritic cells in vitro. J. Clin. Invest. 85: 955-961.
22. McKinnon, J. G., Lalani, A., Sy, L., Bear, H. D. 1993. Generation of cytotoxic T lymphocytes from peripheral blood. Surgery 113: 536-540.
23. Miller, J. S., Verfaillie, C., McGlave, P. 1994. Expansion and activation of human natural killer cells for autologous therapy. J. Hematother. 3: 71-74.
24. Peace, D. J., Smith, J. W., Chen, W., You, S-G., Cosand, W. L., Blake, J., Cheever, M. A. 1994. Lysis of ras oncogene-transformed cells by specific cytotoxic T lymphocytes elicited by primary in vitro immunization with mutated ras peptide. J. Exp. Med. 179: 473-379.
25. + cytotoxic T cells against Epstein-Barr virus-immortalized B cell tumors in SCID mice. Transplantation 58: 629-633.
26. Riddell, S. R., Watanabe, K. S., Goodrich, J. M., Li, C. R., Agha, M. E., Greenberg, P. D. 1992. Restoration of viral immunity in immunodeficient humans by adoptive transfer of T cell clones. Science 257: 238-241.
27. Riddell, S. R., Greenberg, P. D., Overell, R. W., Loughran, T. P., Gilbert, M. J., Lupton, S D., Agosti, J., Scheeler, S., Coombs, R. W., Corey, L. 1992. Phase I study of cellular adoptive immunotherapy using genetically modified HIV-specific T cells for HIV seropositive patients undergoing allogeneic bone marrow transplant. Hum. Gene Ther. 3: 319-338.
28. Risso, A., Smilovich, D., Capra, M. C., Baldissarro, I., Yan, G., Bargellesi, A., Cosulich, M. E. 1991. CD69 in resting and activated T lymphocytes. Its association with a GTP binding protein and biochemical requirements for its expression. J. Immunol. 146: 4105-4114.
29. Rivoltini, L., Kawakami, Y., Robbins, P. F., Mrincola, F. M., Salgaller, M. L., Yannelli, J. R., Rosenberg, S. A. Efficient induction of tumor reactive CTL from peripheral blood and tumor infiltrating lymphocytes of melanoma patients by in vitro stimulation with the human melanoma antigen MART-1 peptide. J. Immunol. (to appear).
30. Rodolfo, M., Bassi, C., Salvi, C., Parmiani, G. 1991. Therapeutic use of a long-term cytotoxic T cell line recognizing a common tumor-associated antigen: The pattern of in vitro reactivity predicts the in vivo effect on different tumors. Cancer Immunol. Immunother. 34: 53-62.
31. Rooney, C. M., Smith, C. A., Ng, C. Y. C., Loftin, S., Li, C., Krance, R. A., Brenner, M. K., Heslop, H. E. 1995. Use of genemodified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 345: 9-13.
32. Rosenberg, S. A., Lotze, M. T., Yang, J. C., Topalian, S. L., Chang, A. E., Schwartzentruber, D J., Aebersold, P., Leitman, S., Linehan, W. M., Seipp, C. A., White, D. E., Steinberg, S. M. 1993. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J. Natl. Cancer Inst. 85: 622-632.
33. Schwartzentruber, D. J., Solomon, D., Rosenberg, S. A.,Topalian. S. L. 1992. Characterization of lymphocytes infiltrating human breast cancer: Specific immune reactivity detected by measuring cytokine secretions. J. Immunother. 12: 1-12.
34. Shimizu, Y., Kuroki, T., Shiomi, S., Kobayashi, K., Monna, T. 1991. Proliferation and cytotoxicity of lectin-induced lymphokine-activated killer (LILAK) cells. J. Gastroenterol. Hepatol. 6: 485-490.
35. Slingluff, Jr., C. L., Darrow, T. L., Seigler, H. F. 1989. Melanoma-specific cytotoxic T cells generated from peripheral blood lymphocytes. Implications of a renewable source of precursors for adoptive cellular immunotherapy. Ann. Surg. 210: 194-202.
36. Stevens, E. J., Jacknin, L., Robbins, P. F., Kawakami, Y., Gamil, M. E., Rosenberg, S. A., Yannelli, J. R. 1995. Generation of tumor-specific CTLs from melanoma patients by using peripheral blood stimulated with allogeneic melanoma tumor cell lines. J. Immunol. 154: 762-771.
37. + cytotoxic T lymphocytes by immunization with syngeneic irradiated HIV-1 envelope derived peptidepulsed dendritic cells. Int. Immunol. 5: 849-857.
38. Thomas, R., Lipsky, P. E. 1994. Human peripheral blood dendritic cell subsets. Isolation and characterization of precursor and mature antigen-presenting cells. J. Immunol. 153: 4016-4028.
39. Topalian, S. L., Muul, L. M., Solomon, D., Rosenberg, S. A. 1987. Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials. J. Immunol. Meth. 102: 127-141.
40. + T lymphocytes on immunological parameters: Lymphocyte subsets and cytotoxic activity. Clin. Immunol. Immunopathol. 68: 263-272.
41. Valiante, N. M., Trinchieri, G. 1993. Identification of a novel signal transduction surface molecule on human cytotoxic lymphocytes. J. Exp. Med. 178: 1397-1406.
42. + T cells: Cytotoxic T-lymphocytes epitopes and precursor frequencies. AIDS 7: 781-786.
43. van der Burg, S. H., Klein, M. R., van de Velde, C. J. H., Kast, W. M., Miedema, F., Melief, C. J. M. Induction of a primary human cytotoxic T-lymphocyte response against a novel conserved epitope in a functional sequence of HIV-1 reverse transcriptase. AIDS 9 (to appear).
44. + cells used for adoptive immunotherapy of patients infected with human immunodeficiency virus. Blood 81: 2085-2092.
45. Young, J. W., Steinman, R. M. 1987. Accessory cell requirements for the mixed-leukocyte reaction and polyclonal mitogens, as studied with a new technique for enriching blood dendritic cells. Cell. Immunol. 111: 167-182.
46. Zhou L-J., Tedder, T. F. 1995. Human blood dendritic cells selectively express CD83, a member of the immunoglobulin superfamily. J. Immunol. 154: 3821-3835.